๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 17 Linyi 5 Suzhou 1 Tianjin 1 Changsha 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing17 Linyi5 Suzhou1 Tianjin1 Changsha1
All 5 locations
Target enrolment
to

Trials with a site in Beijing

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
NCT07784699Healthy Subjects;Overweight or Obesity
Gan & Lee Pharmaceuticals.
Phase 1
112
Beijing
2026-09-04
Not yet open
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
NCT07468396Prostate Cancer
Gan & Lee Pharmaceuticals.
Phase 1
65
Beijing
2026-04-30
Not yet open
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
NCT07493057Obstructive Sleep Apnea (OSA)
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 3
140
Beijing
2026-04-27
Not yet open
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
NCT07387003Type 2 Diabetes (T2DM)
DrugGZR33
Gan & Lee Pharmaceuticals.
Phase 2
345
Beijing
2026-04-10
Recruiting
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
NCT07527078Type 2 Diabetes (T2DM)
Gan & Lee Pharmaceuticals.
Phase 3
350
Beijing
2026-04-07
Not yet open
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy
NCT07501832Obstructive Sleep Apnea (OSA)
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 3
140
Beijing
2026-03-27
Not yet open
A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixentยฎ) in Healthy Adult Male Subjects
NCT07334496Biosimilarity
Gan & Lee Pharmaceuticals.
Phase 1
198
Beijing
2026-03-09
Recruiting
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
NCT07292441Overweight or Obesity
Gan & Lee Pharmaceuticals.
Phase 3
500
Beijing
2026-01-22
Recruiting
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
NCT07128888Obesity or Overweight
Gan & Lee Pharmaceuticals.
Phase 1
60
Beijing
2025-11-17
Recruiting
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovyยฎ) in Adult Obese or Overweight Subjects
NCT07150975Obesity/Overweight in Adult
Gan & Lee Pharmaceuticals.
Phase 3
420
Beijing
2025-09-23
Recruiting
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
NCT07144098Obesity/Overweight
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 1
24
Beijing
2025-08-12
Active, closed
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
NCT07055386Type 2 Diabetes Mellitus (T2DM)
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 2
90
Beijing
2025-08-07
Recruiting
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
NCT07141030Obesity/Overweight
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 1
32
Beijing
2025-04-11
Active, closed
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
NCT06777238Type 2 Diabetes Mellitus (T2DM)
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 3
274
Beijing
2025-01-16
Active, closed
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
NCT06728124Obesity/Overweight
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 3
630
Beijing
2024-12-30
Recruiting
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
NCT06780410Primary Hyperlipidemia
Gan & Lee Pharmaceuticals.
Phase 3
240
Beijing
2024-12-20
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

7 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 17 studies
PhaseStudiesRecruitingShare
Phase 38447.1%
Phase 17341.2%
Phase 22011.8%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Gan & Lee Pharmaceuticals.177
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.